Natural history of primary biliary cirrhosis

Hepatology Research

Volumn 38, Issue 7, 2008, Pages 639-645

  Abe, Masanori ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Natural history; Primary biliary cirrhosis; Symptoms

Indexed keywords

BILIRUBIN; MITOCHONDRION ANTIBODY; PLACEBO; URSODEOXYCHOLIC ACID;

BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS VARICES; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM;

EID: 44649177722     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00351.x     Document Type: Review

References (70)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
2. Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Semin Liver Dis 1997; 17: 13-22.
3. Inoue K, Hirohara J, Nakano T et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995; 15: 70-7.
4. Ahrens EH Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine 1950; 29: 299-364.
5. Sherlock S. Primary biliary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology 1959; 37: 574-86.
6. Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis? Hepatology 1986; 6: 1279-84.
7. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-402.
8. Mattalia A, Quaranta S, Leung PS etal. Characterization of antimitochondrial antibodies in healthy adults. Hepatology 1998; 27: 656-61.
9. Shibata M, Onozuka Y, Morizane T et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol 2004; 39: 255-9.
10. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20: 698-701.
11. Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cirrhosis reassessed: A geographically-based population study. J Hepatol 1999; 30: 402-7.
12. Tsuji K, Watanabe Y, van de Water J et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun 1999; 13: 171-8.
13. Hayase Y, Iwasaki S, Akisawa N et al. Similar anti-mitochondrial antibody reactivity profiles in familial primary biliary cirrhosis. Hepatol Res 2005; 33: 33-8.
14. Lazaridis KN, Juran BD, Boe GM et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46: 785-92.
15. Haga H, Miyagawa-Hayashino A, Taira K et al. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. Hepatol Res 2007; 37 (Suppl. 3): S463-9.
16. Tsuji K, Watanabe Y, Kouno H etal. A case of latent primary biliary cirrhosis. Hepatol Res 2004; 28: 166-9.
17. Onji M, Furukawa S. Significance of study on prevalence of AMA in healthy subjects. J Gastroenterol 2004; 39: 306-8.
18. Fox RA, Scheuer PJ, Sherlock S. Asymptomatic primary biliary cirrhosis. Gut 1973; 14: 444-7.
19. Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72: 1204-7.
20. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7.
21. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990; 98: 1567-71.
22. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20: 707-13.
23. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis. A study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53.
24. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-70.
25. Nyberg A, Loof L. Primary biliary cirrhosis: Clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol 1989; 24: 57-64.
26. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology 1985; 89: 267-71.
27. Nakano T, Inoue K, Hirohara J etal. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol Res 2002; 22: 250-60.
28. Stanca CM, Bach N, Krause C et al. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 2005; 100: 1104-9.
29. Jones DEJ, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55: 536-41.
30. Christensen E, Crowe J, Doniach D et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980; 78: 236-46.
31. Locke GR 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23: 52-6.
32. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-51.
33. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: A prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137-40.
34. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis 2003; 7: 779-94.
35. Itoh S, Ichida T, Yoshida T etal. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998; 13: 257-65.
36. Muratori P, Muratori L, Ferrari R etal. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroentetol 2003; 98: 431-7.
37. Nakamura M, Shimizu-Yoshida Y, Takii Y et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42: 386-92.
38. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
39. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2: 1116-22.
40. Rigamonti C, Shand LM, Feudjo M etal. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-94.
41. Bogdanos DP, Liaskos C, Pares A et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007; 45: 1583.
42. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 1989; 10: 1-7.
43. Murtaugh PA, Dickson ER, Van Dam GM et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 1994; 20: 126-34.
44. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: Development, natural history, and influence on survival. Gastroenterology 1989; 96: 1552-9.
45. Kew MC, Varma RR, Dos Santos HA, Scheuer PJ, Sherlock S. Portal hypertension in primary biliary cirrhosis. Gut 1971; 12: 830-4.
46. Nakanuma Y, Ohta G, Kobayashi K, Kato Y. Histological and histometric examination of the intrahepatic portal vein branches in primary biliary cirrhosis without regenerative nodules. Am J Gastroenterol 1982; 77: 405-13.
47. Abe M, Masumoto T, Ninomiya T et al. Hyperplastic liver nodules associated with early-stage primary biliary cirrhosis mimicking hepatocellular carcinoma. Dig Dis Sci 2000; 45: 1563-7.
48. Takeshita E, Kumagi T, Matsui H et al. Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis. J Gastroenterol 2003; 38: 1060-5.
49. Hiasa Y, Tokumoto Y, Furukawa S et al. Two cases of asymptomatic primary biliary cirrhosis with ascites. Nippon Shokakibyo Gakkai Zasshi 2003; 100: 1400-4.
50. Takeshita E, Matsui H, Shibata N et al. Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients. J Gastroenterol 2004; 39: 1085-9.
51. Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 2005; 54: 407-10.
52. Levy C, Zein CO, Gomez J etal. Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 803-8.
53. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26: 1138-42.
54. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96: 1160-3.
55. Shibuya A, Tanaka K, Miyakawa H et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002; 35: 1172-8.
56. Murata Y, Abe M, Furukawa S et al. Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices. J Gastroenterol 2006; 41: 1220-6.
57. Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 259-64.
58. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-54.
59. Heathcote EJ, Cauch-Dudek K, Walker V et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
60. Combes B, Carithers RL Jr, Maddrey WC et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.
61. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-7.
62. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16.
63. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-9.
64. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113: 884-90.
65. Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenrology 2005; 128: 297-303.
66. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
67. van Hoogstraten HJ, Hansen BE, van Buuren HR et al. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol 1999; 31: 256-62.
68. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006; 101: 2044-50.
69. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999; 354: 1053-60.
70. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72: 1137-40.